Group 1: Industry Insights - The petrochemical and transportation sectors are expected to see continuous improvement in supply and demand, with a positive outlook on the profitability of viscose filament yarns [3] - The semiconductor materials sector is poised for growth due to an increase in fab investments, with the number of 300mm wafer fabs in mainland China projected to rise from 29 in 2024 to 71 by 2027, indicating a significant opportunity for domestic material companies [4] - The agricultural chemicals and private refining sectors are also expected to perform well, alongside the vitamin and methionine segments [3] Group 2: Company Performance - Alibaba Group plans to invest over 380 billion yuan in cloud and AI hardware infrastructure over the next three years, marking the largest investment in this area by a private company in China [5] - Hongsoft Technology is anticipated to benefit from the rapid development of edge AI, with projected revenue of 820 million yuan in 2024, representing a 22% year-on-year increase, and a net profit of 180 million yuan, up 98% [7] - China National Offshore Oil Corporation (CNOOC) has made significant breakthroughs in oil and gas exploration in the Beibu Gulf, with a capital expenditure budget of 125 to 135 billion yuan for 2025 [8] - Andisu's revenue for 2024 is expected to reach 15.5 billion yuan, a year-on-year increase of 18%, with net profit soaring by 2,209% to 1.2 billion yuan [9] - Dongfang Yuhong reported a decline in revenue and net profit for 2024, with total revenue of 2.806 billion yuan, down 14.5%, and a net profit of 110 million yuan, down 95.2% [10]

点击注册小程序 伴随全球地缘政治冲突放缓叠加市场需求恢复，2024年公司蛋氨酸业务保持强劲增长态势，液体蛋氨酸和 固体蛋氨酸销量双双创下历史新高，蛋氨酸产品业务营业收入同比增长24%。在原材料价格上行的压力 下，受益于高效的供应链管理和稳定的工厂生产，公司成功实现毛利率逆势提升，展现出公司卓越的成本 转嫁能力和精益管理水平。此外，维生素业务于2024年年末迎来周期性拐点，价格修复行情初现，或为后 续业绩注入新动能；特种产品板块在奶业市场波动中，公司仍保持4%的稳健增长。在行业景气度持续回暖 背景下，公司盈利能力有望持续改善。 蛋氨酸龙头陆续提价，蛋氨酸价格有望止跌回暖 据中国饲料行业信息网，1月10日安迪苏液蛋提价5%，1月13日新和成固蛋提价15%，1月14日赢创固蛋提 价7%，2月7日赢创蛋氨酸再度上调5%。现货价格方面，截至25年3月5日，国内蛋氨酸均价21.35元/KG， 较年初上涨1.67元/KG(+8%)，随着安迪苏、新和成、赢创等龙头企业蛋氨酸报价陆续提升，现货市场价格 随之止跌回暖。回顾2023年以来蛋氨酸价格走势，受需求走弱影响 23H1蛋氨酸价格持续下跌，23年7月至 24 年2月，受海外 ...

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company's performance in 2024 is driven by strong growth in methionine sales, with a significant increase in both volume and price, leading to a projected net profit of 1.2 billion yuan, a year-on-year increase of 2209% [5][9]. - The company has successfully managed to increase its gross margin despite rising raw material costs, showcasing its effective supply chain management and cost transfer capabilities [5]. - The methionine business has seen a 24% year-on-year revenue growth, with both liquid and solid methionine sales reaching historical highs [5]. - The company is expanding its production capacity with a new solid methionine plant expected to be operational by 2027, which will further strengthen its market position [7]. Summary by Sections Financial Performance - In 2024, the company achieved operating revenue of 15.5 billion yuan, up 18% year-on-year, and a net profit attributable to shareholders of 1.2 billion yuan [5][9]. - The fourth quarter alone saw operating revenue of 4.2 billion yuan, a 17% increase year-on-year [5]. Market Position - The company has increased its market share in methionine from 23% in 2012 to 28% in 2023, solidifying its position as a global leader in the industry [7]. - Recent price increases by leading companies in the methionine market indicate a potential recovery in prices, which had previously been declining [6]. Future Outlook - The company forecasts net profits of 1.52 billion yuan, 1.75 billion yuan, and 2.12 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.57 yuan, 0.65 yuan, and 0.79 yuan [9][10]. - The report anticipates continued improvement in profitability due to the recovery of the vitamin business and stable growth in the specialty products segment [5].

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company's performance in 2024 is driven by strong growth in methionine sales, with a significant increase in both volume and price, leading to a projected net profit of 1.2 billion yuan, a year-on-year increase of 2209% [5][9]. - The company has successfully managed to increase its gross margin despite rising raw material costs, showcasing its effective supply chain management and cost transfer capabilities [5]. - The methionine business has seen a 24% year-on-year revenue growth, with both liquid and solid methionine sales reaching historical highs [5]. - The company is expanding its production capacity with a new solid methionine plant expected to be operational by 2027, which will further strengthen its market position [7]. Summary by Sections Financial Performance - In 2024, the company achieved operating revenue of 15.5 billion yuan, up 18% year-on-year, and a net profit attributable to shareholders of 1.2 billion yuan, up 2209% year-on-year [5][9]. - The fourth quarter alone saw operating revenue of 4.2 billion yuan, a 17% increase year-on-year, and a net profit of 200 million yuan, a 132% increase year-on-year [5]. Market Position - The company has increased its market share in methionine from 23% in 2012 to 28% in 2023, solidifying its position as a global leader in the industry [7]. - The report highlights the company's ability to leverage synergies with Sinochem Group to enhance its competitive edge [5]. Future Outlook - The company forecasts net profits of 1.52 billion yuan, 1.75 billion yuan, and 2.12 billion yuan for 2025, 2026, and 2027 respectively, indicating a strong growth trajectory [9]. - The report anticipates a recovery in methionine prices due to improved supply-demand dynamics, with recent price increases from leading companies in the sector [6].

Investment Rating - The report maintains a "Strong Buy" rating for the company [2][5]. Core Insights - The company achieved a total revenue of 15.534 billion RMB in 2024, representing a year-on-year increase of 17.83%, and a net profit attributable to shareholders of 1.204 billion RMB, reflecting a significant year-on-year growth of 2208.66% [3]. - The functional products segment saw a robust revenue growth of 23.54% to 11.622 billion RMB, driven by strong sales of methionine, with both liquid and solid methionine achieving record sales [3]. - The specialty products segment's revenue increased by 3.61% to 3.913 billion RMB, with stable growth in poultry and swine products, strong sales of selenium products, and good performance in palatability and mycotoxin management products [3]. - The company's overall gross margin improved significantly by 8.83% to 30.21%, with the functional products segment's gross margin increasing by 13 percentage points to 26.02% due to high production stability and effective supply chain management [3]. Production Capacity and Market Position - The company has two methionine production platforms located in Europe and Nanjing, China, with a total annual capacity increase of 80,000 tons from the European platform expansion since Q3 2021 and a new liquid methionine plant in Nanjing with an annual capacity of 180,000 tons that commenced operations in September 2022 [4]. - A new solid methionine plant with an annual capacity of 150,000 tons is under construction in Quanzhou, expected to be operational by 2027, to meet global demand and strengthen the company's leadership in the methionine industry [4]. - The company is also exploring the feasibility of establishing another methionine production platform in the dollar zone to mitigate geopolitical risks [4]. Financial Forecasts - The company is projected to achieve net profits of 1.637 billion RMB, 1.852 billion RMB, and 2.025 billion RMB for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 0.61, 0.69, and 0.75 RMB [5][6]. - The current stock price corresponds to P/E ratios of 18, 15, and 14 for the years 2025, 2026, and 2027, respectively [5].

Investment Rating - The report maintains a "Strong Buy" rating for the company [2][5]. Core Insights - The company achieved a total revenue of 15.534 billion RMB in 2024, representing a year-on-year increase of 17.83%, and a net profit attributable to shareholders of 1.204 billion RMB, reflecting a significant year-on-year growth of 2208.66% [3]. - The functional products segment saw a robust revenue growth of 23.54% to 11.622 billion RMB, driven by strong sales of methionine, with both liquid and solid methionine achieving record sales [3]. - The specialty products segment's revenue increased by 3.61% to 3.913 billion RMB, with stable growth in poultry and swine products, strong sales of selenium products, and good performance in palatability and mycotoxin management products [3]. - The company's overall gross margin improved significantly by 8.83% to 30.21%, with the functional products segment's gross margin increasing by 13 percentage points to 26.02% due to high production stability and effective supply chain management [3]. Production Capacity and Market Position - The company has two methionine production platforms located in Europe and Nanjing, China, with a total annual capacity increase of 80,000 tons from the European platform expansion since Q3 2021 and a new liquid methionine plant in Nanjing with an annual capacity of 180,000 tons that commenced operations in September 2022 [4]. - A new solid methionine plant with an annual capacity of 150,000 tons is under construction in Quanzhou, expected to be operational by 2027, to meet global demand and strengthen the company's leadership in the methionine industry [4]. - The company is also exploring the feasibility of establishing another methionine production platform in the dollar zone to mitigate geopolitical risks [4]. Financial Forecasts - The company is projected to achieve net profits of 1.637 billion RMB, 1.852 billion RMB, and 2.025 billion RMB for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 0.61, 0.69, and 0.75 RMB [5]. - The current stock price corresponds to P/E ratios of 18, 15, and 14 for the years 2025, 2026, and 2027, respectively [5].

Investment Rating - The investment rating for the company is "Outperform the Market" [4][17]. Core Views - The company achieved record-high revenue and significantly improved net profit in 2024, with total revenue reaching 15.534 billion yuan, a year-on-year increase of 17.83%, and net profit attributable to shareholders reaching 1.204 billion yuan, a staggering increase of 2208.66% [1][7]. - The company's methionine production maintained high stability, leading to an increase in gross margin to 30.21%, up 8.83 percentage points year-on-year, and a net margin of 7.76% [1][9]. - The company is expanding its production capacity with a new solid methionine plant expected to be operational by 2027, which will further strengthen its market leadership [2][12]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 15.534 billion yuan, a 17.83% increase from the previous year, and a net profit of 1.204 billion yuan, reflecting a 2208.66% increase [1][7]. - The basic earnings per share (EPS) for 2024 was 0.45 yuan, up 2150.0% year-on-year [1][7]. - The fourth quarter of 2024 saw revenue of 4.158 billion yuan, a 16.5% increase, and a net profit of 201 million yuan, a 132.23% increase [7]. Product Performance - The company's liquid and solid methionine sales both reached historical highs, with the methionine product business revenue growing by 24% [2][11]. - The functional products business achieved revenue of 11.622 billion yuan in 2024, a year-on-year increase of 31.95%, with a gross margin of 26.02% [12]. Strategic Initiatives - The company is implementing a "dual pillar" strategy, with its specialty products business achieving revenue of 3.913 billion yuan in 2024, an 8.87% increase [3][13]. - New projects in specialty products are expected to contribute to continued growth, with a new plant in Nanjing and expansion projects in Europe [3][13]. Future Outlook - The company has adjusted its profit forecasts for 2025-2027, expecting net profits of 1.625 billion yuan, 1.795 billion yuan, and 2.040 billion yuan, representing growth rates of 35.0%, 10.4%, and 13.6% respectively [4][17]. - The projected EPS for 2025, 2026, and 2027 is 0.61 yuan, 0.67 yuan, and 0.76 yuan, with corresponding price-to-earnings ratios of 17.8, 16.1, and 14.2 [4][17].

Investment Rating - The investment rating for the company is "Outperform the Market" [4][17]. Core Views - The company achieved record-high revenue and significantly improved net profit in 2024, with total revenue reaching 15.534 billion yuan, a year-on-year increase of 17.83%, and net profit attributable to shareholders soaring to 1.204 billion yuan, a remarkable growth of 2208.66% [1][7]. - The company's methionine production maintained high stability, contributing to a sales gross margin of 30.21%, up 8.83 percentage points year-on-year, and a net margin of 7.76% [1][9]. - The company is expanding its production capacity with a new solid methionine plant expected to be operational by 2027, which will enhance its market leadership [2][12]. Summary by Sections Financial Performance - In 2024, the company reported a net profit of 1.204 billion yuan, a staggering increase of 2208.66% compared to the previous year, with basic earnings per share rising to 0.45 yuan, up 2150.0% [1][7]. - The fourth quarter of 2024 saw revenue of 4.158 billion yuan, reflecting a year-on-year growth of 16.5% and a net profit of 201 million yuan, up 132.23% [7]. Product Performance - The company's liquid and solid methionine sales both reached historical highs, with the methionine product segment achieving a revenue growth of 24% [2][11]. - The functional products segment generated revenue of 11.622 billion yuan in 2024, a year-on-year increase of 31.95%, with a gross margin of 26.02% [12]. Strategic Initiatives - The company is implementing a "dual pillar" strategy, focusing on the steady development of specialty products, which saw revenue growth of 8.87% in 2024, reaching 3.913 billion yuan [3][13]. - New projects, including a 37,000-ton specialty feed additive plant in Nanjing, are expected to contribute to future growth [13]. Future Outlook - The company anticipates continued growth, with projected net profits of 1.625 billion yuan, 1.795 billion yuan, and 2.040 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 35.0%, 10.4%, and 13.6% [4][17]. - The estimated earnings per share for the same period are expected to be 0.61 yuan, 0.67 yuan, and 0.76 yuan, with corresponding price-to-earnings ratios of 17.8, 16.1, and 14.2 [4][17].

蓝星安迪苏股份有限公司 内部控制审计报告 2024 年 12 月 31 日 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定，建立健全和有效实施内部控制，并评价其有效性是贵公司董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见，并 对注意到的非财务报告内部控制的重大缺陷进行披露。 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 内部控制审计报告 毕马威华振审字第 2500715 号 蓝星安迪苏股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了蓝星 安迪苏股份有限公司（以下简称"贵公司"）2024 年 12 月 31 日的财务报告内部控制的有效 性。 财务报告内部控制审计意见 四、 我们认为，贵公司于 2024 年 12 月 31 日按照《企业内 ...

蓝星安迪苏股份有限公司 自 2024 年 1 月 1 日 至 2024 年 12 月 31 日止年度财务报表 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 审计报告 毕马威华振审字第 2500255 号 关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的事项。这些事 项的应对以对财务报表整体进行审计并形成审计意见为背景，我们不对这些事项单独发表意 见。 第１页，共 6 页 三、关键审计事项 (续) 蓝星安迪苏股份有限公司全体股东： 一、审计意见 我们审计了后附的蓝星安迪苏股份有限公司 (以下简称"安迪苏公司") 财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及 母公司现金流量表、合并及母公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照中华人民共和国财政部颁布的企业会计 准则 (以下简称"企业会计准则") ...